INTRODUCTION

The prevalence of diabetes among Chinese adults is as high as 11.6%, and about 113 million Chinese have type 2 diabetes mellitus (T2DM). Glycated hemoglobin (HbA1c) plays an increasingly important role in the diagnosis and treatment of diabetes. However, the detection of HbA1c depends on the blood glucose concentration and the quality of red blood cells, including shortened red blood cell life, hemolytic anemia, renal anemia, and variant hemoglobin. HbA1c in such patients may not be measured accurately by high performance liquid chromatography (HPLC). Glycated serum albumin (GSA) is a nonenzymatic glycation product of serum albumin upon reaction with glucose. It reflects the postprandial average blood glucose concentration and the average blood glucose level within the
last 2–4 weeks. The GSA level is based on the percentage of glycosylated serum albumin from total serum albumin. When the HbA1c detection is affected by the amount and quality of red blood cells, GSA can more accurately reflect a patient’s average blood glucose level than glycated hemoglobin. Therefore, the detection of GSA is an effective supplement to HbA1c as an indicator for the glucose levels in diabetic patients.

BV is widely used in medical laboratories, including in the assessment of clinical significance of changes in continuous test results from the same individual by RCV, the applicability of population-based reference values through index of individuality (II), and evaluation of analytical performance. BV is highly beneficial for improving the laboratory quality management level. In 2014, the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) questioned the online BV data on the Westgard website about its effectiveness and reliability. The EFLM BV working group then proposed the biological variation data critical appraisal checklist (BIVAC). This checklist is used to standardize operations for assessing existing biological variation studies and guiding future biological variation studies. Currently, based on the checklist, there are nine enzymes, creatinine, and 21 hematological parameters reported in EFLM. According to these papers, all the BV data are less than that reported on Westgard website.

The BV data can confirm if patients treated with antihypertensive or insulin are close to normal levels, indicating that the condition is getting better and the development of complications such as cardiovascular disease or diabetes is unlikely. Therefore, the establishment of effective BV can contribute to the management of chronic diseases such as diabetes. At present, there are many reports on the BV of HbA1c, but the results are contradictory. And there is no report about the biological variation of GSA among the Chinese population. The current study measured the biological variation of HbA1c and GSA in 19 nondiabetic subjects through the standard protocol designed by EFLM.

### 2 | MATERIALS AND METHODS

#### 2.1 | Materials

The research enrolled 19 healthy subjects, including nine males and 10 females, both of the average age 26 years old. All volunteers provided signed informed consents. The inclusion criteria included no familial diabetes, no thalassemia syndrome, or other hemoglobinopathy, females had regular menstrual cycles and did not use hormonal contraceptives, all subjects did not take drugs or smoked, fasting glucose <6.0 mmol/L, body mass index (BMI) <30.0 kg/m². Fasting venous blood (fasting 8–10 h) was collected from the subjects on alternate Mondays. The blood was collected between 9:00 and 9:30 AM, from a subject who first spent ten minutes sitting quietly, by a professional nurse using siliconized vacuum tube (BD Vacutainer®, New Jersey) for GSA and EDTA3K (BD Vacutainer®) for HbA1c. The samples were centrifuged at 3000 g for 10 minutes at 22°C to separate the serum. The serum and whole blood were stored separately at −80°C until further use.

#### 2.2 | Methods

This study received approval of the West China Hospital’s Ethical Review Committee (NO. 228-2015). All the volunteers were signed the informed consent.

We used an enzymatic assay kit (Lucica®GA-L, Tokyo, Japan) to test the GSA levels and HPLC (TOHOSH®, Tokyo, Japan) to test the HbA1c levels. All samples were tested five times.

![Figure 1](image-url)  
**FIGURE 1** The average and 95% confidence interval of HbA1c and GSA in 19 healthy Chinese individuals. × represents males, and ■ represents females.
2.3 Statistical analysis

We assessed the outliers and the distribution of the data. Both the parameters are without outliers, according to Fraser and Harris. The coefficient of variation (CV) was analyzed using ANOVA. The difference between the male and female groups was compared using 95 CI%. If there was no significant difference between male and females, CV was the same in all test subjects. The CV, CV, and CV were calculated using nested ANOVA 95% CI.

The CV = 1/2 × CV, bias (B) = 0.25 × (CV + CV), TE = 1.65 × CV + B.

The reference change value (RCV) and index of individuality (II) were calculated using the formula given by Fraser and Harris:

\[ RCV = \sqrt{2}Z \times \sqrt{CV + CV} \]
\[ II = \sqrt{CV + CV} / CV \]

All the data analyses were performed using SPSS 22.0 (IBM Corp., Armonk, NY, USA) and SAS 9.4 (SAS Institute Inc., Cary, NC, USA).

3 Results

The mean and 95% CI of HbA1c and GSA are shown in Figure 1. The mean of GSA for males was less than females statistically different. The mean levels of albumin were significantly higher in males than females. And there was no difference between males and females of HbA1c (Table 1).

The BV data for all subjects, males alone, and females alone are shown in Table 1. BV estimates were compared with those reported in the Westgard online database. The CV used intra-assay variation to minimize variation. Both of the estimated CV and CV were less than the online database.

We also calculated the variation for males alone and females. The CV of GSA and Alb was closed between males and females, but the CV of HbA1c for males was less than females statistically different. The CV and CV of HbA1c for males were less than females significantly different.

The analytic performance specification (APS) for imprecision, bias, and total error is derived from the BV data shown in Table 2 and compared with the desirable specifications reported in the Westgard database. Based on the BV data, the reference change value (RCV) of GSA and HbA1c was 3.16% and 1.41%, respectively. The index of individuality (II) of GSA and HbA1c was 0.26% and the 0.07, respectively. Both of the II were less than 0.6 (Table 2).

4 Discussion

The mean levels of GSA and Alb in males and females were significantly different, so the reference intervals should be separated.
TABLE 2 APS derived from present research and online database

|                  | APS derived from now research | APS derived from online database |
|------------------|-------------------------------|---------------------------------|
|                  | RCV, % | II, % | Imprecision, % | Bias, % | Total allowable error, % | Imprecision, % | Bias, % | Total allowable error, % |
| GSA, %           | 3.61   | 0.26  | 0.62           | 1.21    | 2.22 | 2.6 | 2.9 | 7.2 |
| Alb, g/dL        | 5.07   | 0.24  | 0.38           | 0.82    | 1.44 | 1.6 | 1.43 | 4.07 |
| HbA1c, %         | 1.41   | 0.07  | 0.15           | 1.08    | 1.32 | 0.9 | 1.5 | 3.0 |

In this research, all estimated BV data were found to be less in comparison with that reported on the Westgard website. Especially for the BV of GSA, compared with the online data, it was decreased (CVI: 1.23% vs 5.2%, CVG: 4.67% vs 10.3%). The CV of Alb and HbA1c was also found to be lesser (Alb: 0.75% vs 3.2%, HbA1c: 0.29% vs 1.9%), and the CVG was also reduced (Alb: 3.18% vs 4.75%, HbA1c: 4.32% vs 5.7%). These differences could be due to several reasons. First, BV varies based on multiple factors, including race, gender, age, growth and development, the economic level, occupation, living habits, and diet structure. Therefore, we employed the checklist proposed by EFLM to reduce variation and ensure reliable and effective data. In this research, we strictly controlled pre-analytical variability factors, such as sample collection time, status, and tourniquet using time, needle diameter, and tube mixing change. Third, there are few sources of biological variation data in the website. At present, the biological variation of GSA in the database is only from one study reported in 1993.13 In the current study, the confidence intervals of GSA were less than that reported before (CVI: 1.19%-1.26% and CVG: 3.77%-4.82%).14

Calculating RCV, II, and analytical quality specifications based on BV data plays an important role in the laboratory. According to these results, if the difference between the two results of GSA measurement is more than 3.6% it is considered to be accompanied by changes in the disease condition, which may help the clinician to further diagnose or treat the condition. It should be noted that the RCV is based on the comparison of the single determination results of an individual with previous results from the same individual, rather than using a population reference interval. II is the ratio of CVI and CVG. When II is >1.4, the reference interval is suitable. When II is <0.6, the reference interval for assessing the results of continuous change is limited, because CVI < CVG, indicating that the analyte has a large individual characteristic and a wide reference interval. In this research, all the II values were <0.6, suggesting that the personalized reference interval based on BV is much more important than the reference interval based on population. Meanwhile, the II of GSA was greater than HbA1c, confirming that the reference interval of GSA is more valuable than HbA1c in the diagnosis and treatment of diabetes.

The well-demonstrated advantages of glycated albumin, compared with HbA1c, are that the changes are more significant and not affected by changes in erythrocyte quality.15 Glycated albumin not only monitors glycemic levels but also has a good correlation with the development of diabetic complications including nephropathy and retinopathy, and can be considered as a marker for assessing atherosclerosis risk.16 In addition, since GSA is the ratio of glycated albumin concentration to total serum albumin, different from fructosamine, GSA is not influenced by the concentration of albumin or other proteins.17 Our research employed strict rules to estimate the BV data than the online website.18 Determining specific analytical performance specifications based on the BV of each test helps to ensure the analytical performance of the laboratory to meet requirements and continuously improve. Moreover, it is beneficial to provide more accurate test results for clinicians.

ACKNOWLEDGMENTS

We thank An Zhenmei for the excellent technical support. This study was support by Department of Laboratory Medicine, West China Hospital of Sichuan University.

AUTHOR CONTRIBUTIONS

Liang Libo and Huang Hengjian research literature and conceived the study. He He involved in protocol and wrote the first draft. Zeng Yuping recruited the volunteers and analyzed the data. Zhang Mei gained the ethical approval and enrolled the volunteers. Wang Xia analyzed the data. Li Xiaoling and Liang Shanshan analyzed the samples, and An Zhenmei and Huang Hengjian approved the final version of the manuscript. All authors reviewed and edited the manuscript.

ETHICAL APPROVAL

Ethics Committee of West China Hospital (NO.228-2015).
REFERENCES

1. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310(9):948-959.

2. Freedman BI, Shihabi ZK, Andries L, et al. Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease. Am J Nephrol. 2010;31(5):375-379.

3. Perich C, Minchinela J, Ricós C, et al. Biological variation database: structure and criteria used for generation and update. Clin Chem Lab Med. 2015;53(2):299-305.

4. Ricós C, Álvarez V, Perich C, et al. Rationale for using data on biological variation. Clin Chem Lab Med. 2015;53(6):863-870.

5. Aarsand AK, Røraas T, Sandberg S. Biological variation – reliable data is essential. Clin Chem Lab Med. 2015;53(2):153-154.

6. Carobene A, Strollo M, Jonker N, et al. Sample collections from healthy volunteers for biological variation estimates’ update: a new project undertaken by the Working Group on Biological Variation established by the European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med. 2016;54(10):1599-1608.

7. Carobene A, Marino I, Coşkun A, et al. The EuBIVAS Project: within- and between-subject biological variation data for serum creatinine using enzymatic and alkaline picrate methods and implications for monitoring. Clin Chem. 2017;63(9):1527.

8. Coşkun A, Carobene A, Kilericik M, et al. Within-subject and between-subject biological variation estimates of 21 hematological parameters in 30 healthy subjects. Clin Chem Lab Med. 2018;56(8):1309-1318.

9. Aarsand AK, Røraas T, Bartlett WA, et al. Harmonization initiatives in the generation, reporting and application of biological variation data. Clin Chem Lab Med. 2018;56(10):1629-1636.

10. Dawson AJ, Sathyapalan T, Atkin SL, Kilpatrick ES. Biological variation of cardiovascular risk factors in patients with diabetes. Diabet Med. 2013;30(10):1172-1180.

11. Ucar F, Erden G, Ginis Z, et al. Estimation of biological variation and reference change value of glycated hemoglobin (HbA1c) when two analytical methods are used. Clin Biochem. 2013;46(15):1548-1553.

12. Yang D, Zhou Y, Yang C. Daytime biological variation of hematological parameters in a healthy Chinese population. Int J Lab Hematol. 2017;39(2):e37.

13. Røraas T, Steve B, Petersen PH, Sandberg S. Biological variation: evaluation of methods for constructing confidence intervals for estimates of within-person biological variation for different distributions of the within-person effect. Clin Chim Acta. 2017;00:166-173.

14. Montagnana M, Paleari R, Danese E, et al. Evaluation of biological variation of glycated albumin (GA) and fructosamine in healthy subjects. Clin Chim Acta. 2013;423(8):1-4.

15. Kim KJ, Lee BW. The roles of glycated albumin as intermediate glycation index and pathogenic protein. Diabetes Metab J. 2012;36(2):98-107.

16. Moon JH, Chae MK, Kim KJ, et al. Decreased endothelial progenitor cells and increased serum glycated albumin are independently correlated with plaque-forming carotid artery atherosclerosis in type 2 diabetes patients without documented ischemic disease. Circ J. 2012;76(9):2273-2279.

17. Kouzuma T, Uemastu Y, Usami T, Imamura S. Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method. Clin Chim Acta. 2004;346(2):135-143.

18. Petersen PH, Fraser CG. Strategies to set global analytical quality specifications in laboratory medicine: 10 years on from the Stockholm consensus conference. Accred Qual Assur. 2010;15(6):323-330.

How to cite this article: Liang L, He H, Zeng Y, et al. Evaluation of biological variation of glycated hemoglobin and glycated albumin in healthy Chinese subjects. J Clin Lab Anal. 2019;33:e22715. https://doi.org/10.1002/jcla.22715